88IV - PR Newswire Asia's news - Medical/Pharmaceuticals


Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ... 2025-07-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe LEATHERHEAD, England , July 4, 2025 /PRNewswire/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark, confirming compliance with European ... 2025-07-04T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
NECC Selects MedMinder to Transform Their Medication Management for Individuals with Autism They Serve NORWOOD, Mass. , July 4, 2025 /PRNewswire/ -- The New England Center for Children (NECC), a globally recognized leader in autism education and research, has contracted with MedMinder, to enhance the ... 2025-07-04T Education Health Care/Hospital Medical/Pharmaceuticals Telecommunications
Fangzhou Tops China's App Store Chart for Healthcare Apps GUANGZHOU, China , July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in the ... 2025-07-03T Health Care/Hospital Medical/Pharmaceuticals Mobile Entertainment
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform BOSTON , July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii , PhD, MBA, ... 2025-07-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy HONG KONG , July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical ... 2025-07-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size ... 2025-07-03T Biotechnology Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20 ins A pproval follows the U.S. FDA's Priority Review and is supported ... 2025-07-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001 Highlights: ... 2025-07-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30 - First p articipants with obesity or o verweight w ith at least one w eight- r elated c omorbidity have been d osed in a U.S. 13-week Phase IIa study of s mall m olecule ... 2025-07-03T Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Medical/Pharmaceuticals